Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst

Uncertainty Leads To Jefferies Maintaining 'Hold' Rating For Lupin

 
• By Urtė Fultinavičiūtė

While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.

Investment decision: sell, buy, do nothing
• Source: Shutterstock

More from Generics

More from Products